Neurological impairments in COVID-19 pandemic

Ivana Bjelobaba, Selma Kanazir

Department for Neurobiology, Institute for Biological Research “Sinisa Stankovic” – National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia

Corresponding author: Ivana Bjelobaba

Department for Neurobiology, Institute for Biological Research “Sinisa Stankovic” – National Institute of Republic of Serbia, Bulevar despota Stefana 142, 11000 Belgrade, Serbia.
Phone: +381 11 2078 340;
Fax: +381 11 2078 433;
E-mail address: ivana.bjelobaba@ibiss.bg.ac.rs

Received 07 September 2020
Accepted 12 October 2020

Abstract

The growing body of data implies that SARS-CoV-2 infection may affect the nervous system. We here present a short, taciturn overview of described neurological impairments related to SARS-CoV-2 infection. While it is obvious that neurological impairments can be diagnosed in a portion of COVID-19 patients, evidence of SARS-CoV-2 neurovirulence in humans is still lacking. The existing data on the incidence of neurological impairments among COVID-19 patients is highly variable, probably because they (most often) come from small, single-center retrospective studies. These data are practically published in real-time, and the question remains when larger studies will be available, given that the pandemic is continuing. We here also shortly address the other issues related to neurological disorders and COVID-19 pandemic, including the concern for people with existing chronic neurological disorders and possible long-term neurological consequences of SARS-CoV-2 infection.

Key words: SARS-CoV-2; COVID-19; Neurotropism; Neurological impairment.

IS SARS-COV-2 NEUROTROPIC?

Coronaviruses are a large family of single-strand RNA viruses, which commonly display spike proteins at their envelopes (electron microscopy visualization of these protrusions helped to name them). Four genuses of coronaviruses are described; almost exclusively, mammals host members of alpha and beta genuses [1]. It is probable that all coronaviruses have a zoonotic origin. Origins of mammalian coronaviruses involve Asian and African continents, with bats serving as the largest viral reservoirs [2]. Human epidemic Severe Acute Respiratory Syndrome coronaviruses SARS-CoV and SARS-CoV-2 belong to betacoronaviruses [1]. Coronaviruses can infect the respiratory, gastrointestinal, hepatic, and central nervous system of other animals (livestock and many wild animal species) and humans. The rapidly accumulating data imply that, in humans, SARS-CoV-2 does not affect only the respiratory tract. Rather, there is a variety of symptoms, including anosmia, ageusia, headache, confusion, delirium, nausea, and diarrhea. Since recently, these more or less common symptoms are often blamed on virus-cell tropism and neurotropism.

The genome of Coronaviruses is polyadenylated and capped, single-stranded positive-sense RNA. The genome of Coronaviruses is unusually big when compared to other RNA viruses and contains at least six open reading frames, coding for structural (S-spike, E-envelope, M-membrane, N-nucleocapsid) and non-structural proteins. Specific coronaviruses also code for some specific structural or non-structural proteins like HE protein in Murine Hepatitis Virus (MHV). Spike proteins are the most important coronavirus proteins for cell tropism of coronaviruses and attachment to cell surface receptors. This enables membrane fusion and entry of the viral genome into the cell [1]. SARS-CoV-2 spike proteins also use this ability to attach to a specific cell receptor. Like SARS-CoV, but with a greater binding efficiency, SARS-CoV-2 reaches the cells by angiotensin-converting enzyme 2 (ACE2) [3]. However, in some strains of MHV, HE protein is also mediating cell tropism and neurotropism [4]. In animals, coronavirus neurotropism is commonly seen in MHV and feline infectious peritonitis virus infections [5]. Moreover, certain strains of MHV serve as models for studying encephalitis and demyelinating diseases [6]. In humans, coronaviruses have been associated with multiple sclerosis development [7, 8], but the interest for coronaviruses neurotropism was recently sparked by the novel SARS-CoV-2 virus.

Multiple points of entry to the central nervous system (CNS) for SARS-CoV-2 have been proposed, and up to now, all mechanisms of invasion are thought to be...
The CNS despite low expression of the transgenic re-
volvizes a rapid and extensive viral spread throughout
infected intranasally. This form of the disease also in-
man ACE2 display a lethal form of the disease when
olfactory bulb [9]. However, mouse transgenes for hu-
neuropathology when inoculated with SARS-CoV [12],
generally, mice fail to develop serious complications or
neurovirulence was shown in mouse animal models.
Thus, the olfactory pathway is considered as a possible
route of entry to the CNS. In addition, the presence of
anosmia in great many COVID-19 patients implies that
rare neurological complications may originate from
there. Indeed, the olfactory pathway and trigeminal
nerve (both of which innervate the nose) are considered
as the routes of coronaviruses entry to the brain

The importance of coronavirus binding to ACE2 for
neurovirulence was shown in mouse animal models.
Generally, mice fail to develop serious complications or
neuropathology when inoculated with SARS-CoV [12],
even though ACE2 is highly expressed in the mouse
olfactory bulb [9]. However, mouse transgenes for hu-
man ACE2 display a lethal form of the disease when
infected intranasally. This form of the disease also in-
volves a rapid and extensive viral spread throughout
the CNS despite low expression of the transgenic re-
ceptor in the brain [13]. No obvious inflammation was
observed, although viral spread was followed by neu-
ronal cell death [12-14]. In these studies, the point of
viral entry to the brain was indeed proposed to be the
olfactory bulb. In support of this hypothesis, the uni-
lateral ablation of the olfactory bulb in mice prevents
MHV CNS invasion on that side of the brain [11].

Similarly, recent studies in the same ACE2 transgen-
ic mouse model imply more severe SARS-CoV-2 infec-
tion and higher replication in various organs, including
the brain [15]. Even when human ACE2 is expressed in
mice lungs only, moderate replication of SARS-CoV-2
was also observed in the brain [16].

However, there is no strong evidence of the pres-
ence of ACE2 mRNA in the human olfactory bulb [9].
Another study found ACE2 protein in the olfactory
bulb but could not localize it in neurons [17]. Furthe-
more, ACE2 is localized in glial cells [9, 17], but the
presence of SARS-CoV was reported in neurons only
[18, 19]. This prompted the hypotheses that SARS-CoV
and SARS-CoV-2 neuroinvasion could be mediated by
vagal afferent innervation of the pulmonary system
[20, 21] or primary afferents of the trigeminal nerve
[22].

An alternative route was recently proposed. Given
the high expression of ACE2 at the enterocytes of the
small intestine and colon and the presence of SARS-
CoV-2 in the gut, involvement of the enteric nervous
system in the virus neurotropism was suggested [22,
23].

Nevertheless, there is little or no evidence of the
presence of the virus in the brain in COVID-19 patients.
Further, there is no direct and specific SARS-CoV-2
damage to the brain in autopsied patients [24-26].

Rather, the pattern of brain pathology resembles those
found in patients with hypoxic respiratory failure, giv-
en that brain vascular injury is a common post-mortem
and MRI finding [25, 27-29]. Some studies found SARS-
CoV-2 mRNA in the brain tissue; however, its low levels
and the absence of specific histopathological findings
implied that this mRNA comes from blood [26, 30]. A
recent report tells of SARS-CoV-2 potential to invade
human brain organoids and claims that SARS-CoV-2
spike protein can be detected by immunohistochemis-
try in the human brain [31]. Conversely, Pellegrini et al.
[32] found that, in brain organoids, SARS-CoV-2 shows
tropism for ACE2 expressing epithelial cells of choroid
plexus, but no tropism for neurons or glial cells. Impor-
tantly, in order to reach the choroid plexus, the virus
has to be present in the blood, which is a rare event
(occurring in about 1% of all COVID-19 patients) [33].

Interestingly, in the cerebrospinal fluid, the pres-
ence of SARS-CoV-2 RNA is not a common finding [34-
37], although in some patients, it shows high titers of
anti-SARS-CoV-2 antibodies [37].

Thus, the neuroinvasive potential of SARS-CoV-2
remains ambiguous, and it is quite possible that the
majority of neurological complications come second-
ary to hypoxia and/or severe systemic inflammation.
The reader of this review should also be aware that
some of the literature cited here still needs to be peer-
reviewed and is currently available as preprint only
(bioRxiv open-access platform).

NEUROLOGICAL MANIFESTATIONS ARE
ACCOMPANYING SARS-COV-2 INFECTIONS

The growing body of data implies that neurological
abnormalities may follow SARS-CoV-2 infection. Up to
now, data is collected in case reports and observation-
al retrospective studies. The major limitation of these
studies is a small sample size coming from a single
center; large scale observational studies on neurologi-
cal disorders in SARS-CoV-2 are still lacking.

The first study on neurological manifestations came
from Wuhan, the epicenter of the COVID-19 pandemic,
and reported that over a third (36.4%) of 214 patients
with confirmed SARS-CoV-2 infection had some neu-
rological symptoms [38]. The most common findings
were dizziness (16.8%), headaches (13.1%), and cere-
brovascular events (5.7%, mostly in severe cases) [38].

Further retrospective studies that included criti-
cally ill patients also revealed wide spectra of neuro-
ological and neuropsychiatric complications [27, 39-42].
A recently published study reported the data ob-
tained from the large TriNetX database, representing
a global health collaborative clinical research plat-
form collecting real-time electronic medical records
data from a network of health care organizations
from January 20th, 2020 (the first reported case in the
USA) to June 10th, 2020. According to this database, out of more than 40,000 COVID-19 patients analyzed, 22.5% of patients had neurological and neuropsychiatric manifestations. The neurological manifestations included headache (3.7%), sleep disorders (3.4%), encephalopathy (2.3%), myalgia (2.0%), pain (1.8%), loss of taste and smell (1.2%), stroke and transient ischemic attack (1.0%) and seizures (0.6%) [43]. A larger European survey done among neurologists from different countries revealed that headache (61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness (29.3%), psychomotor agitation (26.7%), encephalopathy and acute cerebrovascular disorders (21.0%), are the most frequently reported neurological symptoms. Less frequently, dysphagia (11.2%), sleep disorders other than hypersonmia (10.7%), peripheral nerve damage (8.5%), seizures (8.1%), ataxia (7.4%), meningeal signs (5.7%), movement disorders (5.2%), and visual abnormalities (5.1%) were described [44].

The neuropsychiatric issues remain beyond the scope of this short overview but deserve to be mentioned. The prolonged shutdowns, social distancing, and economic problems are probably going to take their toll in the long run and reflect on the mental health of people worldwide. Nalleballe et al. also reported on psychiatric manifestations in COVID-19 patients: anxiety and other related disorders were found in 4.6%, mood disorders in 3.8%, and suicidal ideation in 0.2% patients [43].

In general, neurological manifestations could be classified into CNS (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, epilepsy and seizure, encephalopathy) and peripheral nervous system (PNS) manifestations (taste impairment- hypogeusia/ageusia, smell impairment- hyposmia/anosmia, vision impairment, nerve/muscle pain, and Guillain-Barre syndrome).

**CNS manifestations**

Headaches were reported as the most common neurological symptom with varying prevalence: 3.7% derived from TriNetX database analysis [43], whereas 8% is the mean prevalence derived from different studies [45]. Most likely, headaches are related to hypoxia and decreased cerebral blood flow [43].

Older COVID-19 patients with preexisting medical conditions and poor prognosis are more likely to experience impaired consciousness [46]. Impaired consciousness reported in 9% of COVID-19 patients with poor prognosis [47], while the acute loss of consciousness was linked to a case of intracranial hemorrhage [48].

Seizures were found in around 0.6% of patients [43], most likely are related to increased cytokine levels, but may also come as a rare adverse reaction to antiviral drugs or hydroxychloroquine [46].

Vascular diseases are common preexisting conditions in severe cases of SARS-CoV-2 infections [49]. Nevertheless, it is clear that a variety of acute cerebrovascular disease (CVD) events can be found among COVID-19 patients, including acute ischemic strokes and transient ischemic attack, a cerebral venous sinus thrombosis, and intracerebral hemorrhage. The incidence of CVD greatly varies across different studies, but the common finding is that acute ischemic stroke is the most prevalent one. The other reported CVD symptoms are sporadic and mostly found in severe COVID-19 patients with existing vascular comorbidities [46].

The COVID-19 patients with acute ischemic stroke usually have elevated blood levels of C-reactive protein, D-dimer, antiphospholipid antibodies [41, 49]. Infection of the vascular endothelial cells (virus binding to ACE2 that is enriched in these cells) and subsequent damage to the vasculature, followed by inflammatory cytokine storm and impaired coagulation cascade, was proposed to be a candidate mechanism for stroke-like symptoms [43, 50].

Hypoxic brain damage was diagnosed in 20% of 113 deceased patients with SARS-CoV-2 infection [51]. In general, these events may be related to prolonged hypoxia, which induces blood-brain barrier disruption and micro-hemorrhagic insults to the nervous tissue [52]. This is in concordance with histopathological findings of ischemic changes and microglial activation, without extensive infiltration of inflammatory cells [30].

Sporadic cases of cerebellar ataxia [53, 54] and acute disseminated encephalomyelitis (ADEM) are also reported [55].

**PNS related disorders**

A partial or complete loss of sense of smell and/or taste is reported as the most common PNS related symptom among COVID-19 patients with varying incidence across the studies and between countries [56]. Hypoanosmia and hypoaguesia are common symptoms in many other respiratory infections and, as such, may not have been recognized as SARS-CoV-2 specific at first. Nevertheless, these symptoms come early in the course of the disease and may be the primary cause for alarm in COVID-19 patients [56]. Unlike for two similar human coronaviruses that cause Middle East respiratory syndrome and SARS-CoV, for SARS-CoV-2 firm evidence of infecting olfactory neurons (olfactory sensory neurons do not express ACE2) is still missing. Present data suggest that damage to the olfactory epithelium, rather than neuronal injury underlies clinical anosmia [57, 58], while high ACE2 expression in oral mucosa [59] may account for ageusia.

The rare autoimmune diseases of peripheral nerves, the Guillain-Barré syndrome (GBS), also known...
as acute inflammatory demyelinating polyneuropathy (AIDP), can be triggered by the SARS CoV-2 infection [60]. The symptoms are manifested as the muscle weakness of arms and legs, areflexia, facial weakness in some patients, and changes in sensation or pain, while the acute phase is sometimes characterized by the life-threatening weakness of breathing muscles. The incidence of GBS is very low [43]. GBS and its variants/subtypes were described in 42 COVID-19 patients up to June 30th [60], that is, 73 patients up to July 20th [61]. The mean interval between onset of COVID-19 and GBS symptoms was reported to be 11.5 days, thus confirming the classic post-infectious profile and the mechanisms of pathogenesis that are involved in all dysimmune neuropathies [61].

OTHER CONSIDERATIONS

Concerns have been raised that SARS-CoV-2 infection may have long-term consequences, similar to those humanity has encountered before, with other pathogens. A number of viruses have been implicated in the development of both multiple sclerosis [8] and Parkinson’s disease [62], and thus it has been lately speculated on the possibility that SARS-CoV-2 may serve as a trigger for these diseases [63]. Nevertheless, Parkinson’s disease was associated with encephalitis, which is quite rare among COVID-19 patients [64]. It could be ungrateful, however, to dismiss any long-term neurological consequences of SARS-CoV-2 infection amidst an ongoing pandemic.

Since the start of the pandemic, health care systems around the world are often working beyond their capacities. For people living with disabilities, these circumstances created collateral damage in terms of access to health care services, including rehabilitation [65]. This means that chronic neurological patients receive less attention and care than before [66]. On the other hand, the total number of neuro-emergencies has fallen significantly since the onset of the pandemic [67, 68]. However, it is noted that patients with neuro-emergencies seek medical attention at later times than before the pandemic and that patients with neuro-emergencies should be encouraged to regardless of the symptom severity [67].

Another important aspect of the COVID-19 pandemic is its impact on the growing population of people with age-associated neurodegenerative diseases such as Alzheimer’s disease (AD) and related dementias, especially those accommodated in care facilities. In fact, a small Spanish study recorded a significant worsening of symptoms among patients with Alzheimer’s disease (AD) and mild cognitive impairment [69]. In addition, while old age remains a risk factor for poor outcome in COVID-19 patients [70], statistics imply that older people with dementia are overrepresented in the group of deceased COVID-19 patients [71].

Aside from old age, genetic and environmental factors, as well as viral infections, may pose additional risks for the worsening of existing AD symptoms. Interestingly, the ApoE e4 genotype, an established risk factor for AD [72] was recently found also to increase the risks of severe COVID-19 infection [73]. ApoE e4 affects lipoprotein function and cholesterol metabolism implicated in the pathogenesis of AD [74] and is one of the highly co-expressed genes with ACE2 in alveolar cells in the lungs [75]. Further investigation is needed to understand the link of AD risk factors to COVID-19 severity.

Pertinent to this, research is affected by this pandemic as well as every other aspect of our lives. The pandemic impacted current participants as well as the recruitment of new participants in clinical studies and trials related to dementia and AD [76, 77]. The impact of COVID-19 on basic neuroscience research and research, in general, is yet to be evaluated.

In conclusion, although there is little evidence that SARS-CoV-2 is neurotropic, neurological complications remain a serious issue for a portion of COVID-19 patients. These patients, as well as neurological patients in general, obviously demand special care and treatment, which is difficult to manage in overstrained health care systems. This increases the already heavy burden of COVID-19 pandemics, especially in low- and middle-income countries.

REFERENCES


Neurološki poremećaji i pandemija COVID-19

Ivana Bjelobaba, Selma Kanazir

Odeljenje za neurobiologiju, Institut za biološka istraživanja „Siniša Stanković” – Institut od nacionalnog značaja za Republiku Srbiju, Univerzitet u Beogradu, Bulevar despotu Stefana 142, 11000 Beograd, Srbija

Kratak sažetak

Sve veći broj podataka ukazuje na to da infekcija virusom SARS-CoV-2 može uticati na nervni sistem. Ovde predstavljamo kratak, uzdržan pregled opisanih neuroloških oštećenja povezanih sa SARS-CoV-2 infekcijom. Iako je očigledno da se neurološki poremećaji mogu dijagnostikovati kod dela COVID-19 pacijenata, čvrsti dokazi o neurovirulenciji SARS-CoV-2 još uvek nedostaju. Postojeći podaci o učestalosti neuroloških poremećaja među COVID-19 pacijentima veoma su raznoliki, verovatno zato što (najčešće) potiču iz malih, unicentričnih retrospektivnih studija. Ovi podaci se praktično objavljuju u realnom vremenu i ostaje pitanje kada će biti dostupne veće studije, s obzirom na to da se pandemija nastavlja. Ovde se ukratko bavimo i drugim pitanjima u vezi sa neurološkim poremećajima i pandemijom COVID-19, uključujući tu i uticaj pandemije na ljude sa postojećim hroničnim neurološkim poremećajima i moguće dugoročne neurološke posledice infekcije SARS-CoV-2.

Ključne reči: SARS-CoV-2; COVID-19; Neurotropizam; Neurološki poremećaji.